Healthcare Industry News: HSMN NewsFeed
News Release - February 4, 2020
Serenno Medical Introduces Novel Device for Continuous Automatic Monitoring of Kidney Function of Hospitalized PatientsSentinel™ bedside urine output monitor for early detection and prevention of Acute Kidney Injury reduces patient risk
YOKNEAM, Israel, Feb. 4, 2020 -- (Healthcare Sales & Marketing Network) -- Serenno Medical, developer of medical devices for patient monitoring in a hospital setting, reveals Sentinel™, a novel, robust device for automatic monitoring and detection of kidney damage in hospitalized patients. The Sentinel device is a continuous urine output monitor that measures urine flow rate and volume in real time.
Continuous kidney function assessment allows the early detection of Acute Kidney Injury (AKI), a common condition in hospitalized patients that significantly increases risk of mortality during and after hospitalization. Accurate measurement of urine output (UO) is clinically accepted as the best method for monitoring kidney function. However, UO is currently monitored intermittently and manually by ICU nurses, therefore acute changes in urine flow are difficult to detect. Thus, kidney injury is often detected relatively late, sometimes after it is impossible to prevent further progression.
Sentinel offers a simple and cost-effective solution for the precise, continuous measurement of urine flow rate in real time. The system promotes early detection of kidney injury, while there is still time to intervene and prevent further damage. It aims to automatically and accurately detect small changes in kidney function, taking the workload off the nursing staff while delivering actionable data. The device works in synergy with existing hospital equipment (any catheter and bag) and requires a short and simple, non-invasive installation. It fits the complicated intensive care unit (ICU) and operating room environments and is fully functional in any patient condition or hospital environment.
Prof. Manu Malbrain, MD, PhD, ICU Director, University Hospital Brussels, Co-founder and Former-President WSACS and Co-founder and President of the International Fluid Academy, said, "Urine output measurement is a key parameter to assess kidney function. However, correct urine output determination is often difficult at the bedside and is usually only performed intermittently and manually. Moreover, the kidneys are often the first organ to stop functioning properly, therefore continuous urine output measurement would be a valuable tool in the management of critically ill, unstable patients."
Serenno Medical recently completed its first multicenter clinical trial with the Sentinel system, showing high reliability and accuracy in a wide range of environments and patient conditions, including low and high urine flow rates, regardless of patient position, during surgical procedures, and including continuous monitoring of patients in a mobile hospital bed. The clinical trial, conducted at three ICU units in Sheba and Rabin Medical centers in Israel, included more than 40 patients and over 1,300 hours of monitoring. Results show over 96% accuracy and reliability.
"Serenno has developed a unique product that will bring tremendous value to patients hospitalized in ICU units along with a simple digital solution that will bring great economic value to hospitals," stated Shimon Eckhouse, PhD, Chairman of Serenno Medical. "Serenno's successful clinical trial is a great testament to the quality and performance of the Company's product."
"The successful results of our first clinical trial will allow the company to move forward to manufacturing the device for commercial usage and enable us to bring this best-in-class product to the global medical markets," said Tomer Lark, Co-Founder and CEO of Serenno Medical. "We expect to receive FDA clearance for the system during 2020 and believe that our patent pending device has the potential to become the standard-of-care in the OR and ICU, benefiting millions of patients around the world."
About Acute Kidney Injury (AKI)
Acute Kidney Injury (AKI) affects approximately 19 million patients worldwide every year, with 300K deaths yearly in the US alone. It occurs in 60% of all ICU patients, and 10% of all hospital admissions. AKI triples mortality rates, quadruples risk of readmission and increases length of stay by 50%. AKI is difficult to treat and is irreversible once it is fully manifested. A cardinal sign of failing kidneys is reduced urine flow. However, in order to detect AKI nurses still monitor UO manually, which does not deliver sufficient data to asses kidney function in real time.
About Serenno Medical
Founded in 2017, Serenno Medical is a portfolio company of Alon Medtech Ventures, owned by Dr. Shimon Eckhouse, a renowned entrepreneur and investor in the field of medical devices and medical technologies. The Company develops medical devices for patient monitoring in a hospital setting. Its flagship product is Sentinel™, for the automatic monitoring and detection of kidney damage in hospitalized patients.
Source: Serenno Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.